Somaiya college, University in Mumbai, India

Glenmark Pharmaceuticals on Monday said it was the first pharmaceutical firm to launch in India an intravenous injection formulation, Akynzeo, for the prevention of chemotherapy-induced nausea and vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company.It is a fixed-dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute IV injection. It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV, according to a company statement shared with exchanges on Monday.The drug is already being marketed in the EU, the US, and Australia.Alok Malik, Executive Vice-President for India Formulations, Glenmark Pharmaceuticals, said, "At Glenmark, we are unwavering in our pursuit to help patients and clinicians in cancer care. Chemotherapy is the most common form of cancer treatment, with nausea and vomiting being two of its most debilitating side-effects. Akynzeo IV is a convenient, single-dose, ready-to-dilute I.V. (intravenous) injection that covers, both, the acute and the delayed phases of CINV, thereby enabling patients to avoid multiple antiemetic drugs, and improving compliance."Helsinn Group Chief Executive Officer Giorgio Calderari said, "Akynzeo I.V. would provide a new prophylactic option for patients in India, undergoing chemotherapy and who are at risk of CINV. We are delighted to partner with Glenmark who has an excellent footprint in this region and is trusted with providing the best treatment options for cancer patients."According to the latest National Cancer Registry Programme data, cancer cases in the country are projected to rise by 12.8 per cent by 2025 from 13.9 lakh cases in 2020. Glenmark has a strong legacy of being the first to introduce new and effective prophylactic treatment options for CINV among cancer patients in India. Glenmark Pharmaceuticals is an innovation-driven, global pharmaceutical company with a presence across Branded, Generics, and over-the-counter (OTC) segments; with a focus on therapeutic areas of respiratory, dermatology and oncology.Helsinn is a fully integrated global biopharma company headquartered in Lugano, Switzerland. It is focused on improving the lives of cancer patients all over the world with a leading position in cancer supportive care and a focus on cancer therapeutics and rare diseases.( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Somaiya CollegeFOLLOW

Somaiya college, Latest News

The real estate sector contributes roughly 7 per cent to the national GDP, and it is the largest employment generator for the country by employing more than five crore people. As MMR Real Estate's nodal agency, CREDAI-MCHI has high hopes for the upco ...

RoundGlass, a global Wholistic Wellbeing company has identified cutting-edge wellness trends for the year 2023. Wellbeing researchers and experts at RoundGlass dived deep into wellness science research to pick trends that will define how one lives, h ...

Chandigarh, Jan 23 Chandigarh Administrator and Punjab Governor Banwarilal Purohit on Monday inaugurated north India's largest floating solar ... ...

Paying rich tributes to Subhas Chandra Bose on his birth anniversary, Congress president Mallikarjun Kharge on Monday said that ... ...

New Delhi, Jan 23 Prime Minister Narendra Modi will interact with the Pradhan Mantri Rashtriya Bal Puraskar awardees ... ...

The Supreme Court on Monday assured the petitioners to list the matter pertaining to the ban on Hijab in ... ...

The organized gold jewellery retailers are urging the finance minister to cut gold import duty in the Union Budget 2023-24 as any reduction in duty will help curb gold smuggling, boost exports of gems and jewellery, and empower organised jewellery re ...

Glenmark Pharmaceuticals on Monday said it was the first pharmaceutical firm to launch in India an intravenous injection formulation, ... ...